Anika Therapeutics (ANIK) Net Cash Flow Growth (3y) (2014 - 2026)
Anika Therapeutics (ANIK) Net Cash Flow Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -62.71% |
| 10 | Anika Therapeutics | 203.51 Mn | 136.72 Mn | 19.00 Mn | -35.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.40% |
| Dec 31, 2025 | 31.49% |
| Sep 30, 2025 | 50.76% |
| Jun 30, 2025 | -35.69% |
| Mar 31, 2025 | 1.34% |
| Dec 31, 2024 | -52.45% |
| Sep 30, 2024 | 49.70% |
| Jun 30, 2024 | -60.98% |
| Mar 31, 2024 | -54.17% |
| Dec 31, 2023 | 30.95% |
| Sep 30, 2023 | 34.77% |
| Jun 30, 2023 | -31.78% |
| Mar 31, 2023 | 58.35% |
| Dec 31, 2022 | -26.52% |
| Sep 30, 2022 | -28.18% |
| Jun 30, 2022 | 26.87% |
| Mar 31, 2022 | -38.06% |
| Dec 31, 2021 | -23.58% |
| Sep 30, 2021 | 48.04% |
| Jun 30, 2021 | 29.30% |